Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

奥西默替尼 医学 内科学 T790米 肿瘤科 危险系数 培美曲塞 卡铂 铈替尼 肺癌 化疗 无进展生存期 临床终点 长春瑞滨 吉非替尼 置信区间 表皮生长因子受体 顺铂 随机对照试验 癌症 埃罗替尼 克里唑蒂尼 恶性胸腔积液
作者
David Planchard,Pasi A. Jänne,Ying Cheng,J.C-H. Yang,Noriko Yanagitani,Sang‐We Kim,Shunichi Sugawara,Yan Yu,Yun Fan,Sarayut Lucien Geater,К. К. Лактионов,Chee Khoon Lee,Natalia Valdiviezo,Samreen Ahmed,Jean-Marc Maurel,Igor Andrašina,Jonathan W. Goldman,Dana Ghiorghiu,Yuri Rukazenkov,A. H. Todd,Kunihiko Kobayashi
出处
期刊:The New England Journal of Medicine [New England Journal of Medicine]
卷期号:389 (21): 1935-1948 被引量:36
标识
DOI:10.1056/nejmoa2306434
摘要

Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy.In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non-small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed [500 mg per square meter of body-surface area] plus either cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or to receive osimertinib monotherapy (80 mg once daily). The primary end point was investigator-assessed progression-free survival. Response and safety were also assessed.A total of 557 patients underwent randomization. Investigator-assessed progression-free survival was significantly longer in the osimertinib-chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib-chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. Progression-free survival as assessed according to blinded independent central review was consistent with the primary analysis (hazard ratio, 0.62; 95% CI, 0.48 to 0.80). An objective (complete or partial) response was observed in 83% of the patients in the osimertinib-chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The incidence of grade 3 or higher adverse events from any cause was higher with the combination than with monotherapy - a finding driven by known chemotherapy-related adverse events. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents.First-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
桐桐应助鬼才之眼采纳,获得10
3秒前
朽木完成签到 ,获得积分10
3秒前
lambo完成签到 ,获得积分10
3秒前
lichaoyes完成签到,获得积分10
4秒前
5秒前
yuan完成签到 ,获得积分10
5秒前
自觉的宇完成签到 ,获得积分10
6秒前
huanglm完成签到,获得积分10
6秒前
chcui发布了新的文献求助10
6秒前
三三四发布了新的文献求助10
6秒前
7秒前
try完成签到 ,获得积分10
8秒前
hhhhh完成签到,获得积分20
9秒前
psj完成签到,获得积分10
10秒前
Sience发布了新的文献求助10
12秒前
英姑应助chcui采纳,获得10
14秒前
Jerry完成签到,获得积分10
14秒前
小6s完成签到,获得积分10
14秒前
恰你眉目如昨完成签到 ,获得积分10
17秒前
老神在在完成签到,获得积分10
18秒前
今后应助雨洋采纳,获得10
18秒前
在水一方应助搬运工采纳,获得10
18秒前
小小怪完成签到,获得积分10
18秒前
19秒前
愉快的芷文完成签到 ,获得积分10
21秒前
22秒前
搬运工完成签到,获得积分10
23秒前
CDQ完成签到,获得积分10
24秒前
自然的柠檬完成签到,获得积分10
24秒前
放寒假的完成签到,获得积分10
26秒前
小茗同学发布了新的文献求助10
26秒前
俭朴的发带完成签到,获得积分10
27秒前
慕青应助cuijiawen采纳,获得10
28秒前
benben应助庾稀采纳,获得10
28秒前
kiko完成签到,获得积分10
29秒前
科目三应助朽木采纳,获得10
30秒前
思源应助虚心天思采纳,获得10
33秒前
34秒前
35秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 800
Recherches Ethnographiques sue les Yao dans la Chine du Sud 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
Chinese-English Translation Lexicon Version 3.0 500
Wisdom, Gods and Literature Studies in Assyriology in Honour of W. G. Lambert 400
薩提亞模式團體方案對青年情侶輔導效果之研究 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2391823
求助须知:如何正确求助?哪些是违规求助? 2096649
关于积分的说明 5281811
捐赠科研通 1824208
什么是DOI,文献DOI怎么找? 909793
版权声明 559864
科研通“疑难数据库(出版商)”最低求助积分说明 486146